Recent

% | $
Quotes you view appear here for quick access.

UnitedHealth Group Incorporated Message Board

newtwo99 26 posts  |  Last Activity: 11 hours ago Member since: Jul 23, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • i have finally capitulated. no longer holding a short term target of 42 and longer term target of 52. I have capitulated and now my short term target is 44 and longer term is 60.

  • Use of Hereditary Cancer Panel Testing Increases Detection of Patients at Risk
    Analysis of results from 17,142 breast cancer patients tested with the 25-gene Myriad myRisk™ Hereditary Cancer panel reveals a 104% increase in mutations detected, compared with BRACAnalysis® alone.1
    Outside BRCA1/BRCA2 (48.2% of mutations), the genes most commonly mutated were CHEK2, ATM and PALB2 (approximately 10% of mutations each). Mutations were also detected in seventeen other genes at lower frequencies.1 The following case illustrates the value of comprehensive panel testing v. single syndrome testing in patients with personal and/or family history of multiple cancers.
    Patient A was diagnosed with breast cancer at 45. Her family history was significant for multiple relatives with cancers suggestive of Hereditary Breast and Ovarian Cancer (HBOC) syndrome. Therefore, her physician ordered BRACAnalysis testing, which detected no mutation in BRCA1 or BRCA2.
    Meanwhile, in another city, her unaffected sister’s (Patient B’s) physician, noting the significant family history of cancer, ordered the myRisk™ Hereditary Cancer panel. Myriad’s myRisk™ tests for germline mutations in 25 genes, each associated with an increased risk for one or more of eight cancer sites.
    Patient B tested positive for a deleterious mutation in CDH1, which increases risks for diffuse gastric cancer as well as lobular breast cancer.
    - continued-

  • Reply to

    myriad has stepped up its marketing to physicians

    by newtwo99 Jun 4, 2015 10:56 AM
    newtwo99 newtwo99 Jun 4, 2015 10:57 AM Flag

    Recent NCCN guidelines include surveillance and prevention options for CDH1.2 Preventive gastrectomy and/or upper endoscopy are recommended for risk of gastric cancer. Breast cancer risks from germline CDH1 mutations exceed the 20% lifetime threshold set for screening breast MRI adjuvant to mammography, and recent NCCN guidelines make this explicit for CDH1.
    Patient B’s physician impressed upon her the importance of sharing her test results with family members. First-degree relatives of mutation carriers face a 50% chance to have inherited the same mutation. Patient B shared a copy of her myRisk™ report with her sister, allowing Patient A’s physician to order additional testing. Patient A tested positive for the same CDH1 mutation. Both sisters underwent screening endoscopy, which detected an early stage gastric cancer in Patient A.
    Although germline mutations in CDH1 are uncommon, accounting for 0.5% of mutations detected in the study quoted above1, knowledge of mutation status can have a significant impact on medical management. For this family, comprehensive panel testing with myRisk led to a potentially life-saving intervention. Based on family history alone, upper endoscopy would not have been indicated, and Patient A’s gastric cancer would likely have been detected at a much later stage.
    Bottom Line: Myriad’s 25-gene panel, myRisk™ Hereditary Cancer, doubles the detection of inherited cancer risks in breast cancer patients, compared with single-syndrome testing. A pan-cancer panel approach to hereditary cancer testing has the potential to identify actionable mutations that would be missed by a traditional approach to testing. This new and more comprehensive approach to hereditary cancer testing, made possible by Next Generation Sequencing, can prevent a missed diagnosis and a missed opportunity for meaningful medical intervention.

    from Myriad. not responsible for content.

  • newtwo99 by newtwo99 Jun 25, 2015 8:41 PM Flag

    PR campaign Net has been calling for begins Now! Followed by Prolaris, myRisk, Vectra DA. Quest interest in CDX. Myriad has first and only approved CDX test.

    Quest can have my shares for $52.00

  • Reply to

    nice technical break over the 200 dma

    by netprophecy2 Jul 7, 2015 3:56 PM
    newtwo99 newtwo99 Jul 8, 2015 1:19 PM Flag

    pretty sure there is no exposure to Greece or to China.

  • Huge Biotech Index Rebalance Means Massive Buy Orders for 5 Stocks

  • Prepare! IMHO.

  • short squeeze should continue. short theory is dead. long live the CEO.

  • newtwo99 by newtwo99 Aug 12, 2015 5:32 PM Flag

    Analysis of results from 17,142 breast cancer patients tested with the 25-gene Myriad myRisk™ Hereditary Cancer panel reveals a 104% increase in mutations detected, compared with BRACAnalysis® alone.1
    Outside BRCA1/BRCA2 (48.2% of mutations), the genes most commonly mutated were CHEK2, ATM and PALB2 (approximately 10% of mutations each). Mutations were also detected in seventeen other genes at lower frequencies.

  • newtwo99 by newtwo99 Aug 12, 2015 5:38 PM Flag

    Five new studies on hereditary cancer testing were recently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. The studies demonstrate the increased sensitivity of the Myriad myRisk™ Hereditary Cancer compared to syndrome-specific testing in multiple disease areas:

    1. Outcomes of Clinical Testing of the First 76,574 Patients Tested with myRisk
    2. A Study of Triple-Negative Breast Cancer Patients Tested with myRisk
    3. Assessment of the Clinical Presentation for Patients Discovered to have at Least Two Pathogenic Mutations
    4. Multigene Panel Testing in an Unselected Endometrial Cancer Cohort
    5. Prevalence of Germline Mutations in High Grade ER+/HER2- Breast Cancer Patients diagnosed

  • Johnathan Lancaster, M.D., Ph.D.

    Vice President, Medical Affairs, Myriad Genetic Laboratories

    “We are able to target cancer by matching a patient to a specific therapy based on the biology of his or her own tumor.”

    What is the most important thing patients and physicians need to know about Personalized Medicine?

    Personalized medicine provides the right patient with the right drug, with the right dose at the right time. The enablers of personalized medicine are companion diagnostics—tests that help doctors better predict which treatments will be most effective for individual patients. In cancer, advances in genetics research allow us to look inside a cancer cell to understand what makes it behave the way it does. We are able to target cancer by matching a patient to a specific therapy based on the biology of his or her own tumor.

    How will personalized medicine change health care in the next 10 years?

    Patients are filled with hope when they hear that their doctors are going to select therapies tailored to their individual disease and their individual biology. In the next 10 years we can expect many more companion diagnostics are on the way, as a result of close collaborations between companies like Myriad and biopharmaceutical companies that develop targeted therapies. And that’s incredibly exciting for the future of health care.

  • clear out the short position....

  • Reply to

    myRisk

    by newtwo99 Aug 12, 2015 5:32 PM
    newtwo99 newtwo99 Aug 13, 2015 2:54 PM Flag

    Recent NCCN guidelines include surveillance and prevention options for CDH1. Preventive gastrectomy and/or upper endoscopy are recommended for risk of gastric cancer. Breast cancer risks from germline CDH1 mutations exceed the 20% lifetime threshold set for screening breast MRI adjuvant to mammography, and recent NCCN guidelines make this explicit for CDH1.

  • Reply to

    myRisk

    by newtwo99 Aug 12, 2015 5:32 PM
    newtwo99 newtwo99 Aug 13, 2015 2:55 PM Flag

    Myriad 25-gene panel, myRisk Hereditary Cancer, doubles the detection of inherited cancer risks in breast cancer patients, compared with single-syndrome testing. A pan-cancer panel approach to hereditary cancer testing has the potential to identify actionable mutations that would be missed by a traditional approach to testing. This new and more comprehensive approach to hereditary cancer testing, made possible by Next Generation Sequencing, can prevent a missed diagnosis and a missed opportunity for meaningful medical intervention.

  • newtwo99 by newtwo99 Aug 13, 2015 2:57 PM Flag

    Despite advances in treatment for ovarian cancer, rates of cure for patients with advanced stage disease remain low. In 2015, approximately 14,000 women will die as a result of ovarian cancer, representing ~50% of gynecologic malignancy deaths. The majority of women diagnosed with ovarian cancer are identified at a FIGO Stage III (50%) or Stage IV (13%), with 5-year survival rates of 29-49% and 13%, respectively. Management of patients with advanced stage ovarian cancer usually involves primary cytoreductive surgery followed by first-line chemotherapy with a platinum/taxane regimen. Despite typically positive responses to treatment initially, relapse rate is high, and cure is unlikely.

  • Reply to

    PARP inhibitors

    by newtwo99 Aug 13, 2015 2:57 PM
    newtwo99 newtwo99 Aug 13, 2015 3:03 PM Flag

    Fewer than 27% of newly diagnosed patients with ovarian cancer know their BRCA1 and BRCA2 mutation status.
    However, studies show that in unselected series of patients with ovarian cancer, roughly 13-14.1% carry germline BRCA1 or BRCA2 mutations

  • Reply to

    PARP inhibitors

    by newtwo99 Aug 13, 2015 2:57 PM
    newtwo99 newtwo99 Aug 13, 2015 3:12 PM Flag

    BRACAnalysis CDxTM testing at the time of cancer diagnosis is critical for determining germline BRCA status for all patients with ovarian cancer. A BRACAnalysis CDx result is key to determining targeted chemotherapeutic strategies, including the PARP inhibitor LYNPARZA....

  • newtwo99 by newtwo99 Aug 13, 2015 3:42 PM Flag

    Myriad Genetics announces that the Medicare Administrative Contractor for Myriad, has issued a final local coverage determination for Myriad's Prolaris prognostic test for assessing the aggressiveness of prostate cancer

  • Reply to

    Uptrend to commence!

    by newtwo99 Jul 31, 2015 11:40 PM
    newtwo99 newtwo99 Aug 18, 2015 9:27 AM Flag

    We all must believe!

  • Reply to

    short squeeze in the making ?

    by ch47ady Aug 30, 2015 2:38 AM
    newtwo99 newtwo99 18 hours ago Flag

    Short thesis is dead.

UNH
115.70-1.58(-1.35%)Aug 31 4:00 PMEDT